We are a late-stage biopharmaceutical company leveraging recent scientific insights on our lead therapeutic candidate entinostat, a targeted, epigenetic immunomodulator (EMOD), in the emerging field of immuno-oncology. Due to its distinctive mechanism and preclinical and clinical activity observed to date, we believe entinostat holds great promise as a cornerstone combination therapy for a broad range of cancers.
Syndax is collaborating with Merck to evaluate entinostat in combination with KEYTRUDA® (pembrolizumab) to treat non-small cell lung cancer (NSCLC) and melanoma. Entinostat is also in Phase 3 development, under a special protocol assessment (SPA) agreement, in combination with exemestane to treat HR+ advanced breast cancer, an indication for which entinostat was granted Breakthrough Therapy designation by the U.S. Food and Drug Administration. The Phase 3 study in HR+ advanced breast cancer is being conducted by ECOG-ACRIN under the sponsorship of the NCI and support from Syndax.
Additional NCI- and investigator-sponsored combination clinical trials of entinostat and immuno-oncology agents in solid tumors further establish Syndax’s broad immune-directed program.